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Genotyping with CRISPR-Cas-derived RNA-guided
endonucleases
Jong Min Kim1, Daesik Kim1, Seokjoong Kim2 & Jin-Soo Kim1
Restriction fragment length polymorphism (RFLP) analysis is one of the oldest, most
convenient and least expensive methods of genotyping, but is limited by the availability of
restriction endonuclease sites. Here we present a novel method of employing CRISPR/
Cas-derived RNA-guided engineered nucleases (RGENs) in RFLP analysis. We prepare RGENs
by complexing recombinant Cas9 protein derived from Streptococcus pyogenes with in vitro
transcribed guide RNAs that are complementary to the DNA sequences of interest. Then, we
genotype recurrent mutations found in cancer and small insertions or deletions (indels)
induced in cultured cells and animals by RGENs and other engineered nucleases such as
transcription activator-like effector nucleases (TALENs). Unlike T7 endonuclease I or
Surveyor assays that are widely used for genotyping engineered nuclease-induced mutations,
RGEN-mediated RFLP analysis can detect homozygous mutant clones that contain identical
biallelic indel sequences and is not limited by sequence polymorphisms near the nuclease
target sites.
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R
GENs are derived from the adaptive immune system in
bacteria and archaea known as clustered, regularly inter-
spaced, short palindromic repeats (CRISPR)/CRISPR-
associated protein (Cas)1; they now belong to a family of
genome-editing engineered nucleases that induce site-specific
DNA cleavages in cells and organisms, whose repair via
endogenous DNA double-strand break (DSB) repair systems
gives rise to targeted mutagenesis2,3 and chromosomal re-
arrangements4,5. Unlike zinc-finger nucleases (ZFNs) or trans-
cription activator-like effector (TALE) nucleases (TALENs),
whose DNA sequence specificities are determined by protein
moieties, RGENs recognize and cleave DNA in a targeted manner
using two separate components, that is, a small RNA component
termed CRISPR RNA (crRNA) or single-chain guide RNA
(sgRNA) that hybridizes with a 20-base pair (bp) long target
DNA sequence and the Cas9 protein, derived from Streptococcus
pyogenes, which recognizes the NGG (or, to a lesser extent,
NAG6) trinucleotide sequence known as the protospacer-adjacent
motif (PAM). Thus, an RGEN site can be shown as 50-X20NGG-30,
where X20 corresponds to the crRNA sequence and N is any
base. RGENs consist of Cas9, invariable transactivating crRNA
(tracrRNA) and target-specific crRNA (or sgRNA that consists of
essential portions of tracrRNA and crRNA), and are readily
reprogrammed by replacing crRNA (or sgRNA)7. We and others
have recently used RGENs for genome engineering in bacteria8,
mammalian cells9–12, animals13–19 and plants20–22.
Engineered nuclease-induced mutations are detected by
various methods, which include mismatch-sensitive Surveyor or
T7 endonuclease I (T7E1) assays23, RFLP analysis24, fluorescent
PCR25, DNA melting analysis26 and Sanger and deep sequencing.
The T7E1 and Surveyor assays are widely used but often
underestimate mutation frequencies because the assays detect
heteroduplexes (formed by the hybridization of mutant and wild-
type sequences or two different mutant sequences); they fail to
detect homoduplexes formed by the hybridization of two identi-
cal mutant sequences. Thus, these assays cannot distinguish
homozygous bialleic mutant clones from wild-type cells nor
heterozygous biallelic mutants from heterozygous monoalleic
mutants (Fig. 1a,b). In addition, sequence polymorphisms near
the nuclease target site can produce confounding results because
the enzymes can cleave heteroduplexes formed by hybridization
of these different wild-type alleles. RFLP analysis is free of these
limitations and therefore is a method of choice. Indeed, RFLP
analysis was one of the first methods used to detect engineered
nuclease-mediated mutations24. Unfortunately, however, it is
limited by the availability of appropriate restriction sites.
Here we present a novel method of detecting and quantifying
engineered nucleases-induced mutations in cultured cells and
organisms by employing RGENs in RFLP analysis. Unlike T7E1
or Surveyor assays, RGEN-mediated RFLP analysis can distin-
guish homozygous bialleic mutant clones from wild-type cells and
is not limited by sequence polymorphisms near the nuclease
target sites. In addition, we show that RGEN-RFLP analysis can
be used to genotype naturally-occurring indels and cancer-
associated mutations in human cell lines.
Results
RGEN-mediated RFLP analysis. We reasoned that RGENs can
be employed in RFLP analysis, bypassing the use of conventional
restriction enzymes. New RGENs with desired DNA specificities
can be readily created by replacing crRNA; no de novo purifica-
tion of custom proteins is required once recombinant Cas9
protein is available. Engineered nucleases, including RGENs,
induce small insertions or deletions (indels) at target sites when
the DSBs caused by the nucleases are repaired by error-prone
non-homologous end-joining. RGENs that are designed to














































Figure 1 | Overview of RGEN-RFLP analysis. (a) A conceptual diagram of the T7E1 and RGEN-RFLP assays. Comparison of assay cleavage reactions
in four possible scenarios after engineered nuclease treatment in a diploid cell: (WT) wild type, (Mono) a monoallelic mutation, (Hetero) different
biallelic mutations and (Homo) identical biallelic mutations. Black lines represent PCR products derived from each allele; yellow and red boxes indicate
insertion/deletion mutations generated by non-homologous end-joining. (b) Expected results of T7E1 and RGEN digestion resolved by electrophoresis.
(c) In vitro cleavage assay of a linearized plasmid containing the C4BPB target site bearing indels. DNA sequences of individual plasmid substrates
(bottom panel). The PAM sequence is underlined. Inserted bases are shown in red. Arrows (upper panel) indicate expected positions of DNA bands
cleaved by the wild-type-specific RGEN after electrophoresis.
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efficiently but cannot cleave mutant sequences with indels
(Fig. 1a,b).
We first tested whether RGENs can differentially cleave
plasmids that contain wild type or modified C4BPB target
sequences that harbour 1- to 3-base indels at the cleavage site.
None of the six plasmids with these indels were cleaved by a
C4BPB-specific RGEN9 composed of target-specific crRNA,
tracrRNA and recombinant Cas9 protein (Fig. 1c). In contrast,
the plasmid with the intact target sequence was cleaved efficiently
by this RGEN.
Genotyping indels induced by RGENs via RGEN-RFLP
analysis. To test the feasibility of using RGEN-mediated RFLP
(RGEN-RFLP in short) analysis for the detection of RGEN-
induced mutations, we utilized K562 human cancer cell clones
that had been modified at the C4BPB locus using the C4BPB-
targeting RGEN. Among five C4BPB mutant clones we analysed,
four clones had both wild-type and mutant alleles (hetero-
zygous þ / ) and one clone (#5) had only mutant alleles (com-
pound heterozygous) (Fig. 2a). All of the mutations that occurred
in these clones resulted in the loss of the RGEN target site. Thus,
when the C4BPB mutant clones were subjected to RGEN geno-
typing, PCR amplicons of heterozygous þ / clones that con-
tained both wild-type and mutant alleles were partially digested,
and those of compound heterozygous  / clones that did not
contain the wild-type allele were not digested at all (Fig. 2a). In
line with the plasmid digestion results, even a single-base inser-
tion at the target site blocked the digestion of amplified mutant
alleles by the C4BPB RGEN, showing the high specificity of
RGEN genotyping. In contrast, the PCR products amplified from
wild-type genomic DNA were digested completely by the RGEN.
We subjected the PCR amplicons to the mismatch-sensitive T7E1
assay in parallel. Notably, the T7E1 assay failed to distinguish the
compound heterozygous clone (#5) from the four þ / clones.
We also used RGEN-RFLP to analyse three mutant mice
that had been created by injecting a Foxn1-targeting RGEN into
one-cell stage embryos19. These founder mice carried identical
biallelic mutations at the target site (Fig. 2b). As expected, the
T7E1 assay failed to distinguish these homozygous mutant clones
from the wild-type control, because annealing of the same mutant
sequences forms homoduplexes. In contrast, the RGEN used for
the creation of these mice successfully distinguished them from
the wild-type control: The RGEN cleaved the PCR products
amplified from wild-type genomic DNA completely but did not
cleave those amplified from the mutants at all. Thus, RGEN-RFLP
analysis has a critical advantage over the conventional mismatch-
sensitive nuclease assay in the analysis of clones containing
mutations induced by engineered nucleases.
We also investigated whether RGEN-RFLP analysis is a
quantitative method. Genomic DNA samples isolated from the
C4BPB null clone and the wild-type cells were mixed at various
ratios and used for PCR amplifications. The PCR products were
subjected to RGEN genotyping and the T7E1 assay in parallel
(Fig. 3). As expected, DNA cleavage by the RGEN was
proportional to the wild type to mutant ratio. In contrast, results
of the T7E1 assay correlated poorly with mutation frequencies
inferred from the ratios and were inaccurate, especially at high
mutant %, a situation in which complementary mutant sequences
can hybridize with each other to form homoduplexes.
Next, we designed and tested a new RGEN that targets a highly
polymorphic locus, HLA-B, which encodes Human Leukocyte
Antigen B (also known as MHC class I protein). HeLa cells were
transfected with RGEN plasmids, and the genomic DNA was
subjected to T7E1 and RGEN-RFLP analyses in parallel (Fig. 4a).
T7E1 produced false-positive bands that resulted from sequence
polymorphisms near the target site (Fig. 4b). As expected,
however, the same RGEN used for gene disruption cleaved
PCR products from wild-type cells completely but those from
RGEN-transfected cells partially, indicating the presence of
RGEN-induced indels at the target site. This result shows
that RGEN-RFLP analysis has a clear advantage over the T7E1
assay, especially when it is not known whether target genes have









#1 TATGTGCAATGACCACTACATCCT---CAAGGGCAGCAATCGGAG     WT
TATGTGCAATGACCACTACATCCTCCTCAAGGGCAGCAATCGGAG     +3
#2 TATGTGCAATGACCACTACATCCTCAAGGGCAGCAATCGGAG        WT
TATGTGCAATGACCACTACATC------------AATCGGAG       -12
#3 TATGTGCAATGACCACTACATCCTCAAGGGCAGCAATCGGAG        WT
TATGTGCAATGACCACTACAT---------CAGCAATCGGAG        -9
#4 TATGTGCAATGACCACTACATCCTCAAGGGCAGCAATCGGAG        WT
TATGTGCAATGACCACTACATCC--------AGCAATCGGAG        -8
#5 -------------------------------CAGCAATCGG        -36
TATGTGCAATGACCACTACATCCTTCAAGGGCAGCAATCGG         +1
TATGTGCAATGACCACTACATCCT//67bp//CAAGGGCAGCAATCGG  +67
WT TATGTGCAATGACCACTACATCCTCAAGGGCAGCAATCGGAG WT ACTTCCAGGCTCCACCCGACTGGAGGGCGAACCCCAA 
#69 ACTTCCAGGCTCCACCCGA-----------ACCCCAA    -11
#110 ACTTCCAGGCTCCACCC--------GGCGAACCCCAA    -8


























WT #1 #2 #3 #4 #5 # clone WT #69 #110 #120 # Founder
Figure 2 | Genotyping of RGEN-induced mutations via the RGEN-RFLP technique. (a) Analysis of C4BPB-disrupted clones using RGEN-RFLP and
T7E1 assays. Arrows indicate expected positions of DNA bands cleaved by RGEN or T7E1. The RGEN target site is shown in blue. Red arrows indicate
the RGEN cleavage site. The PAM sequence is underlined. The number of inserted or deleted bases is shown. (b) Analysis of mouse founders that
carried RGEN-induced homozygous biallelic mutations at the Foxn1 gene using RGEN-RFLP and T7E1 assays.
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RGEN-mediated genotyping of ZFN and TALEN-induced
mutations. We then applied RGEN genotyping to the analysis of
mutant mouse founders that had been established using a Pibf1-
specific TALEN27 (Supplementary Fig. 1). We designed and used
two RGENs specific to the TALEN target site (Fig. 5a). One
RGEN recognized the NGG PAM sequence and the other
RGEN recognized the NAG PAM sequence. These two RGENs
successfully detected various mutations, which ranged from
1–27-bp deletions. Unlike the T7E1 assay, RGEN genotyping
enabled differential detection of heterozygous þ / founders (#4
and 5) from compound heterozygous  / founders (#1, 3, 6, 8
and 11) (Fig. 5a). In addition, we used RGENs to detect mutations
induced in human cells by a CCR5-specific ZFN, representing yet
another class of engineered nucleases (Fig. 5b). These results
show that RGENs can detect mutations induced by nucleases
other than RGENs themselves. In fact, we expect that RGENs can
be designed to detect mutations induced by most, if not all,
engineered nucleases. The only limitation in the design of an
RGEN genotyping assay is the requirement for the GG or AG
(CC or CT on the complementary strand) dinucleotide in the
PAM sequence recognized by the Cas9 protein, which occurs
once per 4 bp on average. Indels induced anywhere within the
seed region of several bases in crRNA and the PAM nucleotides
are expected to disrupt RGEN-catalyzed DNA cleavage. Indeed,
we identified at least one RGEN site in most (98%) of the
ZFN and TALEN sites we had reported previously4,23,28,29
(Supplementary Table 1). In contrast, only 36 sites (26%) have
appropriate sites for RFLP analysis using conventional restriction
enzymes.
RGEN-RFLP analysis of naturally occurring variations. RGEN-
RFLP analysis has applications beyond genotyping of engineered
nuclease-induced mutations. We sought to use RGEN genotyping
to detect recurrent mutations found in cancer and naturally
occurring polymorphisms. We chose the human colorectal cancer
cell line, HCT116, which carries a gain-of-function 3-bp deletion
in the oncogenic CTNNB1 gene encoding beta-catenin30. PCR
products amplified from HCT116 genomic DNA were cleaved
partially by both wild-type-specific and mutant-specific RGENs,
in line with the heterozygous genotype in HCT116 cells (Fig. 6a).
In sharp contrast, PCR products amplified from DNA from HeLa
cells harbouring only wild-type alleles were digested completely
by the wild-type-specific RGEN and were not cleaved at all by the
mutation-specific RGEN.
We also noted that HEK293 cells harbour the 32-bp deletion
(del32) in the CCR5 gene, which encodes an essential co-receptor
of HIV infection: Homozygous del32 CCR5 carriers are immune
to HIV infection31. We designed one RGEN specific to the
del32 allele and the other to the wild-type allele. As expected, the
wild-type-specific RGEN cleaved the PCR products obtained
from K562, SKBR3 or HeLa cells (used as wild-type controls)
completely but those from HEK293 cells partially (Supplementary
Fig. 2a), confirming the presence of the uncleavable del32 allele in
HEK293 cells. Unexpectedly, however, the del32-specific RGEN
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Figure 3 | Quantitative comparison of RGEN-RFLP analysis with T7E1
assays. Genomic DNA samples from wild type and C4BPB-disrupted
K562 cells (clone #5 in Fig. 2a) were mixed in various ratios and
subjected to RGEN-RFLP and T7E1 assays. Data points are represented


































Figure 4 | Genotyping of RGEN-induced mutations at the highly polymorphic HLA-B locus using RGEN-RFLP. (a) HeLa cells were transfected
with a HLA-B-specific RGEN. RGEN-induced mutations were analysed using RGEN-RFLP and T7E1 assays in parallel. (b) The DNA sequence,
which surrounds the RGEN target site, is that of a PCR amplicon from HeLa cells. Polymorphic positions are shown in red. The RGEN target site is
shown in blue. The PAM sequence is underlined. Arrows indicate PCR primer sequences.
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cleaved the PCR products from wild-type cells as efficiently as
those from HEK293 cells. Interestingly, this RGEN had an off-
target site with a single-base mismatch immediately downstream
of the on-target site (Supplementary Fig. 2). These results suggest
that RGENs can be used to detect naturally occurring indels
but cannot distinguish sequences with single-nucleotide poly-
morphisms or point mutations due to their off-target effects.
Genotyping of single-nucleotide variations via RGEN-RFLP.
To genotype oncogenic single-nucleotide variations32 using
RGENs, we attenuated RGEN activity by employing a single-
base mismatched guide RNA instead of a perfectly matched RNA.
RGENs that contained the perfectly matched guide RNA specific
to the wild-type sequence or mutant sequence cleaved both
sequences (Supplementary Figs 3 and 4). In contrast, RGENs that
contained a single-base mismatched guide RNA distinguished the
two sequences, enabling genotyping of three recurrent oncogenic
point mutations in the KRAS, PIK3CA and IDH1 genes in human
cancer cell lines (Fig. 6b and Supplementary Fig. 5a,b). In
addition, we were able to detect point mutations in the BRAF and
NRAS genes using RGENs that recognize the NAG PAM
sequence (Supplementary Fig. 5c,d). We believe that we can use
RGEN-RFLP to genotype almost any, if not all, mutations or
polymorphisms in the human and other genomes.
Discussion
Here we showed that RGEN-RFLP analysis can be used for
genotyping both engineered nuclease-induced mutations and
naturally occurring variations in cultured cells and animals.
Unlike the T7E1 assay, RGEN-RFLP analysis is not limited by
sequence polymorphisms near the nuclease target sites and
distinguishes homozygous biallelic mutant clones from wild-type
clones and heterozygous monoallelic mutant (þ / ) clones from
heterozygous biallelic mutant ( / ) clones. These features can
make RGEN-RFLP a method of choice for detecting indels
induced by RGENs and other nucleases. We observed, however,
that RGENs often cannot distinguish off-target DNA sequences
with a single-nucleotide mismatch. This off-target DNA cleavage
TCATACAGATGATGTCTCATCATCAGAGGAGCGAGAAGGTAAAGTCAAAATCA GTCATCCTCATCCTGATAAACTGCAAAAGGCTGA
Target site-NGG-RGEN







































Figure 5 | RGEN-mediated genotyping of ZFN/TALEN-induced mutations. (a) Genotyping of mouse founders generated by a PIBF-targeting TALEN.
The left and right half-sites of the PIBF TALEN are shown in red and blue, respectively. The PAM sequence recognized by Cas9 is underlined.
(b) RGEN-mediated genotyping of ZFN-induced mutations. The left and right half-sites of the CCR5-ZFN are shown in red and blue, respectively.











































GTAGTTGGAGCTGGTGGCGTAGG wild type 
ACTACCACAGCTCCT---CTGAGTGG c.133-135 del TCT
ACTACCACAGCTCCTTCTCTGAGTGG wild type
ACTACCACAGCTCCTTCTCTGAGTGG wild type
Figure 6 | Genotyping of oncogenic mutations via RGEN-RFLP analysis. (a) A recurrent mutation (c.133–135 deletion of TCT) in the human CTNNB1
gene in HCT116 cells was detected by RGENs. (b) Genotyping of the KRAS substitution mutation (c.34G4A) in the A549 cancer cell line with RGENs
that contain mismatched guide RNA. Mismatched nucleotides are shown in red. HeLa cells were used as a negative control. Arrows indicate DNA
bands cleaved by RGENs. DNA sequences confirmed by Sanger sequencing are shown.
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by RGENs does not limit the utility of RGEN-RFLP for
measuring the frequency of nuclease-induced mutations because
error-prone non-homologous end-joining repair of DSBs rarely
produces single-nucleotide substitutions. We employed attenu-
ated guide RNAs that contain a single-base mismatch rather than
perfectly matched guide RNAs to distinguish the wild-type
sequences from the mutant sequences with substitutions. This
result is consistent with our recent report that RGENs transfected
into cultured human cells discriminate on-target sites from off-
target sites that differ by two bases efficiently but not those that
differ by a single base33. We also found that, at least partially due
to off-target DNA cleavage, RGEN concentrations need to be
optimized for each RFLP analysis (Supplementary Table 2).
Next-generation sequencing platforms are now widely used for
genotyping in basic and biomedical research, including genotyp-
ing of mutations induced by engineered nucleases, and will soon
be used broadly for diagnostics. RFLP analysis, however, may
remain a method of choice in many settings, because it is a fast
and inexpensive method with no requirement for special
equipment. RGEN-RFLP analysis will broaden the utility of this
convenient and robust method in a wide range of applications,
enabling genotyping of both naturally occurring and nuclease-
induced mutations.
Methods
RGEN components. crRNA and tracrRNA were prepared by in vitro transcription
using MEGAshortcript T7 kit (Ambion) according to the manufacturer’s instruc-
tion. Transcribed RNAs were resolved on an 8% denaturing urea-PAGE gel. The
gel slice containing RNA was cut out and transferred to elution buffer. RNA was
recovered in nuclease-free water followed by phenol:chloroform extraction,
chloroform extraction and ethanol precipitation. Purified RNA was quantified by
spectrometry. Templates for crRNA were prepared by annealing an oligonucleotide
whose sequence is shown as 50-GAAATTAATACGACTCACTATAGGX20GTT-
TTAGAGCTATGCTGTTTTG-30 , in which X20 is the target sequence, and its
complementary oligonucleotide. The template for tracrRNA was synthesized by
extension of forward and reverse oligonucleotides (50-GAAATTAATACGACTC-
ACTATAGGAACCATTC AAAACAGCATAGCAAGTTAAAATAAGGCTA-
GTCCG-30 and 50-AAAAAAAGCACCGACT CGGTGCCACTTTTTCAAGTT-
GATAACGGACTAGCCTTATTTTAACTTGCTATG-30) using Phusion poly-
merase (New England Biolabs).
Recombinant Cas9 protein. Recombinant Cas9 protein was purchased from
ToolGen, Inc. or purified from E. coli. The Cas9 DNA construct that encodes
S. pyogenes Cas9 fused to the His6-tag at the C terminus was inserted in the pET-
28a expression vector. The recombinant Cas9 protein was expressed in E. coli strain
BL21(DE3) cultured in LB medium at 25 C for 4 h after induction with 1mM
IPTG. Cells were harvested and resuspended in buffer containing 20mM Tris
(PH 8.0), 500mM NaCl, 5mM imidazole and 1mM PMSF. Cells were frozen in
liquid nitrogen, thawed at 4 C and sonicated. After centrifugation, Cas9 protein in
the lysate was bound to Ni-NTA agarose resin (Qiagen), washed with buffer
containing 20mM Tris (pH 8.0), 500mM NaCl and 20mM imidazole, and eluted
with buffer containing 20mM Tris (pH 8.0), 500mM NaCl and 250mM
imidazole. Purified Cas9 protein was dialyzed against 20mM HEPES (pH 7.5),
150mM KCl, 1mM DTT and 10% glycerol and analysed by SDS–PAGE.
T7 endonuclease I assay. The T7E1 assay was performed as described pre-
viously23. In brief, PCR products amplified using genomic DNA were denatured at
95 C, reannealed at 16 C and incubated with 5 units of T7 Endonuclease I
(New England BioLabs) for 20min at 37 C. The reaction products were resolved
using 2–2.5% agarose gel electrophoresis. The DNA sequences of PCR primers are
shown in Supplementary Table 3. Full gel images are shown in Supplementary
Figs 6–10.
RGEN-RFLP assay. PCR products (100–150 ng) were incubated for 60min at
37 C with optimized concentrations (Supplmentary Table 2) of Cas9 protein,
tracrRNA, crRNA in 10ml NEB buffer 3 (1 ). After the cleavage reaction, RNase
A (4 mg) was added, and the reaction mixture was incubated for 30min at 37 C to
remove RNA. Reactions were stopped with 6 stop solution buffer containing
30% glycerol, 1.2% SDS and 100mM EDTA. Products were resolved with 1–2.5%
agarose gel electrophoresis and visualized with EtBr staining. Full gel images are
shown in Supplementary Figs 6–10.
Plasmid cleavage assay. Restriction enzyme-treated linearized plasmid (100 ng)
was incubated for 60min at 37 C with Cas9 protein (0.1 mg), tracrRNA (60 ng) and
crRNA (25 ng) in 10ml NEB 3 buffer (1 ). Reactions were stopped with 6 stop
solution containing 30% glycerol, 1.2% SDS and100mM EDTA. Products were
resolved with 1% agarose gel electrophoresis and visualized with EtBr staining.
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Corrigendum: Genotyping with CRISPR-Cas-derived
RNA-guided endonucleases
Jong Min Kim, Daesik Kim, Seokjoong Kim & Jin-Soo Kim
Nature Communications 5:3157 doi: 10.1038/ncomms4157 (2014); Published 20 Jan 2014; Updated 6 Feb 2015
This Article contains an error in Fig. 3. The labels ‘T7E1’ and ‘RGEN-RFLP’ appear on the wrong gels. The correct version of this figure
appears below.
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